Public Health Law and Emergency Powers

The Constitutional Architecture of Public Health Authority

US public health law is layered. The Constitution gives most public health authority to the states, while the federal government has more limited but still substantial powers.

State police powers — The constitutional foundation of state public health authority. The Tenth Amendment reserves to the states all powers not granted to the federal government. State police powers — the authority to regulate for public health, safety, welfare, and morals — are foundational. This is why most direct public health interventions (vaccine mandates, quarantines, disease reporting requirements, restaurant inspections, water quality regulation) happen at the state level.

Jacobson v. Massachusetts (1905) established the modern doctrine that state public health authority can override individual rights when:

• The intervention has a real and substantial relationship to a legitimate public health goal
• The intervention is not arbitrary or oppressive
• The intervention is not plainly inappropriate to the situation

Jacobson has been cited as supportive precedent in essentially every major US public health case for over a century. It survived challenges during the polio era, HIV/AIDS, and COVID-19. It remains good law.

Federal authority is more limited and operates through specific constitutional powers:

• Commerce Clause — Federal authority to regulate interstate commerce extends to public health measures affecting commerce (drug regulation, food safety, interstate disease control)
• Spending Clause — Federal authority to attach conditions to federal funding extends to public health requirements on grant recipients (Medicaid conditions, CDC grant conditions)
• Treaty Power — Federal authority to implement treaties extends to international public health obligations (WHO International Health Regulations, biosecurity treaties)
• Necessary and Proper Clause — General authority to execute other constitutional powers

Federal public health agencies — CDC, FDA, NIH, OSHA — derive their authority from specific statutes implementing these constitutional powers. The HHS Secretary's authority during public health emergencies, for example, comes from the Public Health Service Act and various emergency-specific statutes.

Federalism in practice means that during a public health crisis, both federal and state authorities act simultaneously. The federal government may declare a Public Health Emergency, but states issue the actual stay-at-home orders. The FDA may approve a vaccine, but states determine who gets prioritized for access. The CDC may issue recommendations, but states decide whether to follow them. This division creates both flexibility and dysfunction — the COVID-19 response showed both.

---

Emergency Powers and the Public Health Emergency Declaration

When a major public health threat emerges, federal and state authorities can invoke emergency powers that significantly expand the normal regulatory toolkit.

Federal Public Health Emergency (PHE) declaration. Authorized by Section 319 of the Public Health Service Act. Declared by the HHS Secretary. Allows the federal government to:

• Take emergency action to investigate, treat, or prevent the spread of disease
• Reassign federal personnel to respond to the emergency
• Provide grants and contracts to address the emergency
• Issue Emergency Use Authorizations (EUAs) for unapproved medical products
• Adjust Medicare/Medicaid coverage rules
• Waive certain regulatory requirements

The PHE declaration was renewed repeatedly during COVID-19, ultimately running from January 2020 to May 2023.

Stafford Act emergency declaration. Authorized by the President. Triggers FEMA response capabilities and broader federal disaster authorities. During COVID-19, both PHE (HHS) and Stafford Act (FEMA) declarations were in effect simultaneously, allowing coordinated federal response.

State emergency powers. Each state has its own emergency powers framework, typically in state statutes. State governors can declare emergencies that:

• Suspend specific state laws or regulations
• Issue stay-at-home, business closure, or mask orders
• Activate state National Guard for response
• Compel cooperation from state and local agencies
• Implement quarantine and isolation

State emergency authorities are typically broad in declaration but face increasing legal challenge in implementation. Many states have, since 2020, passed legislation limiting governors' emergency authority — requiring legislative consent for emergencies beyond a specific duration, or restricting specific public health interventions like business closures.

The legal limits on emergency power are increasingly contested. The Supreme Court's 2022 decision in NFIB v. OSHA struck down a federal vaccine-or-test mandate for large employers, holding that OSHA exceeded its statutory authority. The decision signaled judicial skepticism toward expansive emergency interpretations of statutory authority — a skepticism that public health law scholars argue could constrain future pandemic responses.

The fundamental question: in an era of increasing political polarization, can public health emergency powers remain functional? Jacobson presupposes that public health measures are essentially uncontroversial. The COVID era demonstrated that they are not. The legal architecture built on assumptions of public deference to medical authority faces ongoing stress.

---

The Hodge Thesis: Public Health Law as Outdated Infrastructure

This module's framing borrows directly from a body of scholarship led by Professor James G. Hodge Jr. at the Sandra Day O'Connor College of Law at Arizona State University. Hodge's work — and that of allied scholars like Lawrence Gostin at Georgetown — develops a sustained argument that US public health law has failed to keep pace with biomedical innovation, leaving emerging biotechnologies in a regulatory gray zone where neither traditional public health authority nor standard pharmaceutical regulation adequately applies.

The central observations:

Statutory drift. Most foundational public health statutes were written for an era of communicable disease (cholera, smallpox, tuberculosis) and traditional medical practice. They don't adequately anticipate gene therapy, CRISPR, synthetic biology, or the ethical issues these raise.

Federalism gaps. State public health authority is designed for traditional medical and behavioral interventions. When biotechnology operates at federal level (FDA approval) but is used at state level (clinical practice), responsibility for monitoring, safety, equity, and access falls between the cracks.

Equity blindspots. Public health law operates largely on assumptions of universal access and standard treatments. When gene therapies cost $2-3 million per patient (BP3), the existing legal infrastructure doesn't address — or sometimes even acknowledge — who can actually access these therapies. The legal framework for ensuring equitable access to biotech innovations is essentially absent.

Speed mismatches. Public health law evolves through statutes (slow), regulations (medium), and court decisions (variable). Biotechnology evolves through research and product development (fast). The pace mismatch means law is structurally behind, often by years or decades.

Capacity erosion. State and local public health departments have been chronically underfunded for decades. Even when legal authority exists, the institutional capacity to monitor, evaluate, and respond to emerging biotech may not. This was acutely visible during COVID-19 — and is even more concerning for slower-moving biotech challenges.

The Hodge thesis isn't that current public health law is useless. It's that current public health law was built for problems that aren't the most important problems anymore. Emerging biotechnologies — gene therapies, gene drives, AI-assisted biotech, personalized medicine at scale, designer microbiomes — operate in legal spaces that the existing framework barely covers.

The reform agenda flowing from this critique includes:

• Modernizing public health statutes to explicitly address emerging biotechnologies
• Strengthening federal-state coordination with clearer authority allocation for biotech
• Building equity considerations into biotech approvals, not just safety and efficacy
• Capacity-building for state and local public health departments to meaningfully monitor and respond to biotech
• International harmonization to prevent regulatory arbitrage (biotech development moving to less-regulated jurisdictions)

This is the policy agenda your independent research with Hodge contributes to. The module exists in part because public health law literacy is essential to the work.

---

The COVID-19 Stress Test and Its Lessons

COVID-19 was the most extensive real-world test of US public health law in a century. Several lessons have emerged.

EUA at scale. The pandemic showed both the value and the limits of Emergency Use Authorization. EUAs enabled rapid deployment of vaccines, monoclonal antibodies, and diagnostics in ways that would have been impossible under standard FDA approval timelines. They also operated with reduced transparency and lower evidentiary standards than full approval — and the public confusion about what "EUA" meant for safety contributed to vaccine hesitancy.

Vaccine mandates and Jacobson. Jacobson survived as legal authority but faced unprecedented practical resistance. Courts upheld most state and employer vaccine mandates (state mandates for healthcare workers, for example) but struck down some federal interpretations (the OSHA mandate). Vaccine mandate enforcement turned out to be politically costly in ways that Jacobson hadn't anticipated.

Federal-state coordination breakdowns. State responses varied dramatically — both in legal authority used and in actual interventions implemented. The same drug, vaccine, or test could be required in one state and prohibited in another. The legal frameworks couldn't bridge the political variation.

Misinformation and public health authority. The public health legal framework presupposes that authoritative public health information will reach the public and influence behavior. The COVID-era information environment — fractured social media, motivated political messaging, and active disinformation — disrupted that presupposition. Public health law doesn't have effective tools for addressing this. Whether new tools should exist is a contested policy question.

Health equity exposed. COVID-19 dramatically illustrated existing health inequities — disparate impacts by race, income, occupation, and geography. The public health legal framework was largely powerless to address these patterns in real time. Building equity into emergency response remains an unsolved policy challenge.

Long-term emergency questions. The PHE declaration ran for more than three years. The legal framework wasn't really designed for sustained emergencies of that length. What public health authority should look like for prolonged challenges — not single acute events, but multi-year crises — remains underdeveloped.

The honest summary: US public health law functioned in COVID-19 but not without significant strain, and not in ways that inspire confidence about future challenges. The next pandemic — or the next major biotech challenge requiring sustained public health response — will encounter the same structural limitations.

---

Wait, Actually...

The Spanish Flu pandemic of 1918 happened entirely within the legal framework that Jacobson established just thirteen years earlier.

That framework hadn't been tested at the scale of a global pandemic when it was created. The 1918 flu killed an estimated 50 million people worldwide and roughly 675,000 Americans (more than all 20th century American war casualties combined). The legal response, in retrospect, was a mixed bag — some cities (St. Louis, San Francisco) used aggressive public health measures including mandatory mask laws and business closures with reasonable success; others (Philadelphia, most famously) failed to act early and saw catastrophic mortality.

Yet Jacobson enabled the legal authority that worked when it worked. Cities with strong public health departments and political will to act had the legal tools they needed. Cities without those institutional foundations didn't develop them — and Jacobson didn't change that.

The 1918 experience suggests something the COVID era reinforced: legal authority is necessary but not sufficient for effective public health response. The institutions that exercise that authority, the political climate they operate in, and the public trust that legitimizes their action all matter as much as the underlying legal framework.

The pessimistic reading: even if we fix the legal architecture, the institutional and political problems remain. The optimistic reading: fixing the legal architecture creates conditions where institutional and political work can succeed. Most public health scholars hold both readings simultaneously.

---